The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback